Last reviewed · How we verify

AN2728 Topical Ointment, 0.5% BID

Pfizer · Phase 2 active Small molecule

AN2728 Topical Ointment, 0.5% BID is a JAK inhibitor Small molecule drug developed by Pfizer. It is currently in Phase 2 development for Moderate to severe plaque psoriasis.

AN2728 is a topical ointment that targets the Janus kinase (JAK) pathway to modulate inflammation.

AN2728 is a topical ointment that targets the Janus kinase (JAK) pathway to modulate inflammation. Used for Moderate to severe plaque psoriasis.

At a glance

Generic nameAN2728 Topical Ointment, 0.5% BID
SponsorPfizer
Drug classJAK inhibitor
TargetJAK
ModalitySmall molecule
Therapeutic areaDermatology
PhasePhase 2

Mechanism of action

By inhibiting JAK enzymes, AN2728 reduces the production of pro-inflammatory cytokines, thereby alleviating symptoms of psoriasis. This mechanism of action is specific to the treatment of moderate to severe plaque psoriasis.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about AN2728 Topical Ointment, 0.5% BID

What is AN2728 Topical Ointment, 0.5% BID?

AN2728 Topical Ointment, 0.5% BID is a JAK inhibitor drug developed by Pfizer, indicated for Moderate to severe plaque psoriasis.

How does AN2728 Topical Ointment, 0.5% BID work?

AN2728 is a topical ointment that targets the Janus kinase (JAK) pathway to modulate inflammation.

What is AN2728 Topical Ointment, 0.5% BID used for?

AN2728 Topical Ointment, 0.5% BID is indicated for Moderate to severe plaque psoriasis.

Who makes AN2728 Topical Ointment, 0.5% BID?

AN2728 Topical Ointment, 0.5% BID is developed by Pfizer (see full Pfizer pipeline at /company/pfizer).

What drug class is AN2728 Topical Ointment, 0.5% BID in?

AN2728 Topical Ointment, 0.5% BID belongs to the JAK inhibitor class. See all JAK inhibitor drugs at /class/jak-inhibitor.

What development phase is AN2728 Topical Ointment, 0.5% BID in?

AN2728 Topical Ointment, 0.5% BID is in Phase 2.

What are the side effects of AN2728 Topical Ointment, 0.5% BID?

Common side effects of AN2728 Topical Ointment, 0.5% BID include Application site reactions, Headache, Nausea.

What does AN2728 Topical Ointment, 0.5% BID target?

AN2728 Topical Ointment, 0.5% BID targets JAK and is a JAK inhibitor.

Related